Presbia PLC (NASDAQ:LENS) was founded in 2014 and is headquartered in Dublin, Ireland. It has 24 full-time employees. It is a medical equipment/instrument and consumable company engaged in the development and sales of ophthalmic equipment. The main products are optical lens implants for the treatment of presbyopia. Into things.
Presbia PLC (LENS):
Presbia is a medical device company dedicated to developing presbyopia correction-Presbia Flexivue Microlens™-an innovative solution for common age-related functions that cannot read or focus on close objects. The 3mm diameter lens is implanted in a corneal pocket created by a femtosecond laser.
The Presbia Flexivue Microlens™ solution responds to the market’s demand for safe, effective, fast and easy to learn and implement surgical procedures. The solution can be used with surgical equipment already used in most eye surgery centers. The most distinctive feature is that Presbia Flexivue Microlens™ is designed to be replaceable, which means that the lens can be removed and replaced without any residual effects on the eyes.
Presbia Flexivue Microlens™ has obtained the European Union’s CE certification, allowing the lens to be marketed all over Europe. However, Presbia Flexivue Microlens™ has not yet been approved by the FDA and has not been commercialized in the United States.
Presbia is an ISO 13485 approved company.
Presbia mainly operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada and Germany.